following an abbreviated submission
linagliptin plus metformin combination tablets (Jentadueto®) is accepted for restricted use within NHS Scotland.
Indication under review: for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control when insulin and metformin alone do not provide adequate glycaemic control.
SMC restriction: to use in patients for whom a combination of linagliptin and metformin is an appropriate choice of therapy and the fixed doses are considered appropriate.
For patients in whom combination therapy with linagliptin and metformin is appropriate, it has the potential to reduce the pill burden at no additional cost.
Download detailed advice51KB (PDF)
Medicine details
- Medicine name:
- linagliptin + metformin (Jentadueto)
- SMC ID:
- 1057/15
- Indication:
- for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control when insulin and metformin alone do not provide adequate glycaemic control.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 08 June 2015